NRX Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.25
- Today's High:
- $0.2761
- Open Price:
- $0.2761
- 52W Low:
- $0.221
- 52W High:
- $1.54
- Prev. Close:
- $0.262
- Volume:
- 663327
Company Statistics
- Market Cap.:
- $24.35 million
- Book Value:
- -0.035
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -87.1%
- Return on Equity TTM:
- -346.7%
Company Profile
NRX Pharmaceuticals Inc had its IPO on 2017-12-04 under the ticker symbol NRXP.
The company operates in the Healthcare sector and Biotechnology industry. NRX Pharmaceuticals Inc has a staff strength of 0 employees.
Stock update
Shares of NRX Pharmaceuticals Inc opened at $0.28 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.25 - $0.28, and closed at $0.26.
This is a -0.38% slip from the previous day's closing price.
A total volume of 663,327 shares were traded at the close of the day’s session.
In the last one week, shares of NRX Pharmaceuticals Inc have slipped by -12.42%.
NRX Pharmaceuticals Inc's Key Ratios
NRX Pharmaceuticals Inc has a market cap of $24.35 million, indicating a price to book ratio of 4.5546 and a price to sales ratio of 0.
In the last 12-months NRX Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-36399000. The EBITDA ratio measures NRX Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, NRX Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -87.1% with a return of equity of -346.7%.
In Q2, NRX Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
NRX Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.52 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NRX Pharmaceuticals Inc’s profitability.
NRX Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.6134. Its price to sales ratio in the trailing 12-months stood at 0.
NRX Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $19.81 million
- Total Liabilities
- $22.62 million
- Operating Cash Flow
- $2000.00
- Capital Expenditure
- $2000
- Dividend Payout Ratio
- 0%
NRX Pharmaceuticals Inc ended 2024 with $19.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $19.81 million while shareholder equity stood at $-2808000.00.
NRX Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $22.62 million in other current liabilities, 80000.00 in common stock, $-242753000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.97 million and cash and short-term investments were $14.97 million. The company’s total short-term debt was $12,692,000 while long-term debt stood at $0.
NRX Pharmaceuticals Inc’s total current assets stands at $19.79 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $6000.00 compared to accounts payable of $2.21 million and inventory worth $-6000.00.
In 2024, NRX Pharmaceuticals Inc's operating cash flow was $2000.00 while its capital expenditure stood at $2000.
Comparatively, NRX Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.26
- 52-Week High
- $1.54
- 52-Week Low
- $0.221
- Analyst Target Price
- $4.67
NRX Pharmaceuticals Inc stock is currently trading at $0.26 per share. It touched a 52-week high of $1.54 and a 52-week low of $1.54. Analysts tracking the stock have a 12-month average target price of $4.67.
Its 50-day moving average was $0.35 and 200-day moving average was $0.75 The short ratio stood at 1.96 indicating a short percent outstanding of 0%.
Around 3602.5% of the company’s stock are held by insiders while 423.2% are held by institutions.
Frequently Asked Questions About NRX Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.